POWERFUL CURE RATES IN JUST 8 WEEKS1,2*
In Treatment-Naïve Patients
SVR12 Range: 95%-99%
Based on an integrated, pooled analysis of GT 1-6 TN NC and CC adult patients across 8 clinical trials.
0.1% on-treatment virologic failure (n=1/1248)2
0.6% relapse (n=7/1226)2
Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation.1
*Liver or kidney transplant recipients are not eligible for an 8-week regimen.
Cure = sustained virologic response (SVR12); HCV RNA <LLOQ at 12 weeks after the end of treatment. Relapse = HCV RNA ≥LLOQ after end-of-treatment response among subjects who completed treatment.
AASLD and IDSA have not endorsed, and are not sponsors of, or otherwise affiliated with, MAVYRET or AbbVie Inc.